开云app官网登录入口网页版-官方正版

[GetPortalCommentsPageByObjectIdResponse(id=2225394, encodeId=10cb222539483, content=9.01 submit 9.02 with editor 9.12 还是 with editor，这啥情况啊能不能痛快点, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=025b6459612, createdName=ms5000001558887674, createdTime=Thu Sep 12 14:34:51 CST 2024, time=2024-09-12, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2225009, encodeId=a17b22250095a, content=审稿速度:3.0 偏重的研究方向：肿瘤 经验分享：2024-7-31 submit 2024-8-9 under review 2024-8-22 under review 2024-9-5 一个审稿人完成审稿 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e3ef6418566, createdName=ms3000000081429133, createdTime=Tue Sep 10 15:35:43 CST 2024, time=2024-09-10, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1231418, encodeId=a1c912314180d, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：泌尿系统肿瘤 经验分享：投稿一个多月就decision, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=cd131929695, createdName=石冰水寒, createdTime=Fri Jul 08 23:50:37 CST 2022, time=2022-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2223093, encodeId=1b89222309325, content=20240826从cancer letters转投过来的，20240827变成with editor, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57c56585599, createdName=ms1000000366960686, createdTime=Thu Aug 29 21:47:22 CST 2024, time=2024-08-29, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2224802, encodeId=91ba2224802bb, content=6.4投稿之后we 6.9 ur 8.23 小修当天修回 9.9 仍然是Revision Submitted to Journal （9.6发过催稿信官方回复）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b5c8431154, createdName=ms2000002142798745, createdTime=Mon Sep 09 12:24:12 CST 2024, time=2024-09-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2224164, encodeId=32d5222416446, content=已经投了半个月了还是with editor,真的拒的话能不能给个痛快啊这也太慢了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=21a65422215, createdName=小L爱科研, createdTime=Thu Sep 05 10:48:15 CST 2024, time=2024-09-05, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2217940, encodeId=137f221e940f6, content=偏重的研究方向：肿瘤 经验分享：7.16 submit 7.17 with editor 7.25 with editor 状态没变时间变 7.31 dip 是不是拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79a19302650, createdName=派大星的海绵**, createdTime=Thu Aug 01 10:44:13 CST 2024, time=2024-08-01, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2218424, encodeId=2c2b221842440, content=偏重的研究方向：肿瘤 经验分享：7.21投稿，7.23 with editor, 7.31 Decision in Process,这是不是要被拒了呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/4AEFTDxtTLcicl4SBQst8KS16TvccEdKUdYlCe0Rsu73iaW3GgcO1wZmD6PDPwf4a9kadNYiaTic1iadbgAicWWgFzBQ/132, createdBy=026e2391043, createdName=lialunxi, createdTime=Sun Aug 04 17:12:42 CST 2024, time=2024-08-04, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2221228, encodeId=995a2221228c3, content=偏重的研究方向：肿瘤 经验分享：7.31 提交然后 with editor，8.18 decision in process 是不是要被拒了…, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1668229032, createdName=ms7000001281118581, createdTime=Mon Aug 19 01:26:38 CST 2024, time=2024-08-19, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2218959, encodeId=aa8f221895946, content=7.30投了1篇；7.31 with editor； 8.6 under review，公众号查询一个审稿员接受邀请；看大家这个状态会很长时间，揪心。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9f99339818, createdName=ms7000000778834027, createdTime=Wed Aug 07 17:05:11 CST 2024, time=2024-08-07, status=1, ipAttribution=湖北省)]

2024-09-12 ms5000001558887674 来自江苏省

9.01 submit
9.02 with editor
9.12 还是 with editor，这啥情况啊能不能痛快点

1 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=2225394, encodeId=10cb222539483, content=9.01 submit 9.02 with editor 9.12 还是 with editor，这啥情况啊能不能痛快点, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=025b6459612, createdName=ms5000001558887674, createdTime=Thu Sep 12 14:34:51 CST 2024, time=2024-09-12, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2225009, encodeId=a17b22250095a, content=审稿速度:3.0 偏重的研究方向：肿瘤 经验分享：2024-7-31 submit 2024-8-9 under review 2024-8-22 under review 2024-9-5 一个审稿人完成审稿 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e3ef6418566, createdName=ms3000000081429133, createdTime=Tue Sep 10 15:35:43 CST 2024, time=2024-09-10, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1231418, encodeId=a1c912314180d, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：泌尿系统肿瘤 经验分享：投稿一个多月就decision, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=cd131929695, createdName=石冰水寒, createdTime=Fri Jul 08 23:50:37 CST 2022, time=2022-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2223093, encodeId=1b89222309325, content=20240826从cancer letters转投过来的，20240827变成with editor, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57c56585599, createdName=ms1000000366960686, createdTime=Thu Aug 29 21:47:22 CST 2024, time=2024-08-29, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2224802, encodeId=91ba2224802bb, content=6.4投稿之后we 6.9 ur 8.23 小修当天修回 9.9 仍然是Revision Submitted to Journal （9.6发过催稿信官方回复）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b5c8431154, createdName=ms2000002142798745, createdTime=Mon Sep 09 12:24:12 CST 2024, time=2024-09-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2224164, encodeId=32d5222416446, content=已经投了半个月了还是with editor,真的拒的话能不能给个痛快啊这也太慢了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=21a65422215, createdName=小L爱科研, createdTime=Thu Sep 05 10:48:15 CST 2024, time=2024-09-05, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2217940, encodeId=137f221e940f6, content=偏重的研究方向：肿瘤 经验分享：7.16 submit 7.17 with editor 7.25 with editor 状态没变时间变 7.31 dip 是不是拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79a19302650, createdName=派大星的海绵**, createdTime=Thu Aug 01 10:44:13 CST 2024, time=2024-08-01, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2218424, encodeId=2c2b221842440, content=偏重的研究方向：肿瘤 经验分享：7.21投稿，7.23 with editor, 7.31 Decision in Process,这是不是要被拒了呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/4AEFTDxtTLcicl4SBQst8KS16TvccEdKUdYlCe0Rsu73iaW3GgcO1wZmD6PDPwf4a9kadNYiaTic1iadbgAicWWgFzBQ/132, createdBy=026e2391043, createdName=lialunxi, createdTime=Sun Aug 04 17:12:42 CST 2024, time=2024-08-04, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2221228, encodeId=995a2221228c3, content=偏重的研究方向：肿瘤 经验分享：7.31 提交然后 with editor，8.18 decision in process 是不是要被拒了…, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1668229032, createdName=ms7000001281118581, createdTime=Mon Aug 19 01:26:38 CST 2024, time=2024-08-19, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2218959, encodeId=aa8f221895946, content=7.30投了1篇；7.31 with editor； 8.6 under review，公众号查询一个审稿员接受邀请；看大家这个状态会很长时间，揪心。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9f99339818, createdName=ms7000000778834027, createdTime=Wed Aug 07 17:05:11 CST 2024, time=2024-08-07, status=1, ipAttribution=湖北省)]

2024-09-10 ms3000000081429133 来自河南省

审稿速度:3.0
偏重的研究方向：肿瘤
经验分享：2024-7-31 submit
2024-8-9 under review
2024-8-22 under review
2024-9-5 一个审稿人完成审稿

3 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2225394, encodeId=10cb222539483, content=9.01 submit 9.02 with editor 9.12 还是 with editor，这啥情况啊能不能痛快点, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=025b6459612, createdName=ms5000001558887674, createdTime=Thu Sep 12 14:34:51 CST 2024, time=2024-09-12, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2225009, encodeId=a17b22250095a, content=审稿速度:3.0 偏重的研究方向：肿瘤 经验分享：2024-7-31 submit 2024-8-9 under review 2024-8-22 under review 2024-9-5 一个审稿人完成审稿 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e3ef6418566, createdName=ms3000000081429133, createdTime=Tue Sep 10 15:35:43 CST 2024, time=2024-09-10, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1231418, encodeId=a1c912314180d, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：泌尿系统肿瘤 经验分享：投稿一个多月就decision, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=cd131929695, createdName=石冰水寒, createdTime=Fri Jul 08 23:50:37 CST 2022, time=2022-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2223093, encodeId=1b89222309325, content=20240826从cancer letters转投过来的，20240827变成with editor, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57c56585599, createdName=ms1000000366960686, createdTime=Thu Aug 29 21:47:22 CST 2024, time=2024-08-29, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2224802, encodeId=91ba2224802bb, content=6.4投稿之后we 6.9 ur 8.23 小修当天修回 9.9 仍然是Revision Submitted to Journal （9.6发过催稿信官方回复）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b5c8431154, createdName=ms2000002142798745, createdTime=Mon Sep 09 12:24:12 CST 2024, time=2024-09-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2224164, encodeId=32d5222416446, content=已经投了半个月了还是with editor,真的拒的话能不能给个痛快啊这也太慢了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=21a65422215, createdName=小L爱科研, createdTime=Thu Sep 05 10:48:15 CST 2024, time=2024-09-05, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2217940, encodeId=137f221e940f6, content=偏重的研究方向：肿瘤 经验分享：7.16 submit 7.17 with editor 7.25 with editor 状态没变时间变 7.31 dip 是不是拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79a19302650, createdName=派大星的海绵**, createdTime=Thu Aug 01 10:44:13 CST 2024, time=2024-08-01, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2218424, encodeId=2c2b221842440, content=偏重的研究方向：肿瘤 经验分享：7.21投稿，7.23 with editor, 7.31 Decision in Process,这是不是要被拒了呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/4AEFTDxtTLcicl4SBQst8KS16TvccEdKUdYlCe0Rsu73iaW3GgcO1wZmD6PDPwf4a9kadNYiaTic1iadbgAicWWgFzBQ/132, createdBy=026e2391043, createdName=lialunxi, createdTime=Sun Aug 04 17:12:42 CST 2024, time=2024-08-04, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2221228, encodeId=995a2221228c3, content=偏重的研究方向：肿瘤 经验分享：7.31 提交然后 with editor，8.18 decision in process 是不是要被拒了…, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1668229032, createdName=ms7000001281118581, createdTime=Mon Aug 19 01:26:38 CST 2024, time=2024-08-19, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2218959, encodeId=aa8f221895946, content=7.30投了1篇；7.31 with editor； 8.6 under review，公众号查询一个审稿员接受邀请；看大家这个状态会很长时间，揪心。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9f99339818, createdName=ms7000000778834027, createdTime=Wed Aug 07 17:05:11 CST 2024, time=2024-08-07, status=1, ipAttribution=湖北省)]

2022-07-08 石冰水寒

审稿速度:2.0 | 投稿命中率:75.0
偏重的研究方向：泌尿系统肿瘤
经验分享：投稿一个多月就decision

120 13

展开13条回复

[GetPortalCommentsPageByObjectIdResponse(id=2225394, encodeId=10cb222539483, content=9.01 submit 9.02 with editor 9.12 还是 with editor，这啥情况啊能不能痛快点, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=025b6459612, createdName=ms5000001558887674, createdTime=Thu Sep 12 14:34:51 CST 2024, time=2024-09-12, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2225009, encodeId=a17b22250095a, content=审稿速度:3.0 偏重的研究方向：肿瘤 经验分享：2024-7-31 submit 2024-8-9 under review 2024-8-22 under review 2024-9-5 一个审稿人完成审稿 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e3ef6418566, createdName=ms3000000081429133, createdTime=Tue Sep 10 15:35:43 CST 2024, time=2024-09-10, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1231418, encodeId=a1c912314180d, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：泌尿系统肿瘤 经验分享：投稿一个多月就decision, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=cd131929695, createdName=石冰水寒, createdTime=Fri Jul 08 23:50:37 CST 2022, time=2022-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2223093, encodeId=1b89222309325, content=20240826从cancer letters转投过来的，20240827变成with editor, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57c56585599, createdName=ms1000000366960686, createdTime=Thu Aug 29 21:47:22 CST 2024, time=2024-08-29, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2224802, encodeId=91ba2224802bb, content=6.4投稿之后we 6.9 ur 8.23 小修当天修回 9.9 仍然是Revision Submitted to Journal （9.6发过催稿信官方回复）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b5c8431154, createdName=ms2000002142798745, createdTime=Mon Sep 09 12:24:12 CST 2024, time=2024-09-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2224164, encodeId=32d5222416446, content=已经投了半个月了还是with editor,真的拒的话能不能给个痛快啊这也太慢了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=21a65422215, createdName=小L爱科研, createdTime=Thu Sep 05 10:48:15 CST 2024, time=2024-09-05, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2217940, encodeId=137f221e940f6, content=偏重的研究方向：肿瘤 经验分享：7.16 submit 7.17 with editor 7.25 with editor 状态没变时间变 7.31 dip 是不是拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79a19302650, createdName=派大星的海绵**, createdTime=Thu Aug 01 10:44:13 CST 2024, time=2024-08-01, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2218424, encodeId=2c2b221842440, content=偏重的研究方向：肿瘤 经验分享：7.21投稿，7.23 with editor, 7.31 Decision in Process,这是不是要被拒了呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/4AEFTDxtTLcicl4SBQst8KS16TvccEdKUdYlCe0Rsu73iaW3GgcO1wZmD6PDPwf4a9kadNYiaTic1iadbgAicWWgFzBQ/132, createdBy=026e2391043, createdName=lialunxi, createdTime=Sun Aug 04 17:12:42 CST 2024, time=2024-08-04, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2221228, encodeId=995a2221228c3, content=偏重的研究方向：肿瘤 经验分享：7.31 提交然后 with editor，8.18 decision in process 是不是要被拒了…, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1668229032, createdName=ms7000001281118581, createdTime=Mon Aug 19 01:26:38 CST 2024, time=2024-08-19, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2218959, encodeId=aa8f221895946, content=7.30投了1篇；7.31 with editor； 8.6 under review，公众号查询一个审稿员接受邀请；看大家这个状态会很长时间，揪心。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9f99339818, createdName=ms7000000778834027, createdTime=Wed Aug 07 17:05:11 CST 2024, time=2024-08-07, status=1, ipAttribution=湖北省)]

2024-08-29 ms1000000366960686 来自辽宁省

20240826从cancer letters转投过来的，20240827变成with editor

21 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=2225394, encodeId=10cb222539483, content=9.01 submit 9.02 with editor 9.12 还是 with editor，这啥情况啊能不能痛快点, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=025b6459612, createdName=ms5000001558887674, createdTime=Thu Sep 12 14:34:51 CST 2024, time=2024-09-12, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2225009, encodeId=a17b22250095a, content=审稿速度:3.0 偏重的研究方向：肿瘤 经验分享：2024-7-31 submit 2024-8-9 under review 2024-8-22 under review 2024-9-5 一个审稿人完成审稿 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e3ef6418566, createdName=ms3000000081429133, createdTime=Tue Sep 10 15:35:43 CST 2024, time=2024-09-10, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1231418, encodeId=a1c912314180d, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：泌尿系统肿瘤 经验分享：投稿一个多月就decision, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=cd131929695, createdName=石冰水寒, createdTime=Fri Jul 08 23:50:37 CST 2022, time=2022-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2223093, encodeId=1b89222309325, content=20240826从cancer letters转投过来的，20240827变成with editor, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57c56585599, createdName=ms1000000366960686, createdTime=Thu Aug 29 21:47:22 CST 2024, time=2024-08-29, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2224802, encodeId=91ba2224802bb, content=6.4投稿之后we 6.9 ur 8.23 小修当天修回 9.9 仍然是Revision Submitted to Journal （9.6发过催稿信官方回复）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b5c8431154, createdName=ms2000002142798745, createdTime=Mon Sep 09 12:24:12 CST 2024, time=2024-09-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2224164, encodeId=32d5222416446, content=已经投了半个月了还是with editor,真的拒的话能不能给个痛快啊这也太慢了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=21a65422215, createdName=小L爱科研, createdTime=Thu Sep 05 10:48:15 CST 2024, time=2024-09-05, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2217940, encodeId=137f221e940f6, content=偏重的研究方向：肿瘤 经验分享：7.16 submit 7.17 with editor 7.25 with editor 状态没变时间变 7.31 dip 是不是拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79a19302650, createdName=派大星的海绵**, createdTime=Thu Aug 01 10:44:13 CST 2024, time=2024-08-01, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2218424, encodeId=2c2b221842440, content=偏重的研究方向：肿瘤 经验分享：7.21投稿，7.23 with editor, 7.31 Decision in Process,这是不是要被拒了呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/4AEFTDxtTLcicl4SBQst8KS16TvccEdKUdYlCe0Rsu73iaW3GgcO1wZmD6PDPwf4a9kadNYiaTic1iadbgAicWWgFzBQ/132, createdBy=026e2391043, createdName=lialunxi, createdTime=Sun Aug 04 17:12:42 CST 2024, time=2024-08-04, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2221228, encodeId=995a2221228c3, content=偏重的研究方向：肿瘤 经验分享：7.31 提交然后 with editor，8.18 decision in process 是不是要被拒了…, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1668229032, createdName=ms7000001281118581, createdTime=Mon Aug 19 01:26:38 CST 2024, time=2024-08-19, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2218959, encodeId=aa8f221895946, content=7.30投了1篇；7.31 with editor； 8.6 under review，公众号查询一个审稿员接受邀请；看大家这个状态会很长时间，揪心。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9f99339818, createdName=ms7000000778834027, createdTime=Wed Aug 07 17:05:11 CST 2024, time=2024-08-07, status=1, ipAttribution=湖北省)]

2024-09-09 ms2000002142798745 来自江苏省

6.4投稿之后we
6.9 ur
8.23 小修当天修回
9.9 仍然是Revision Submitted to Journal （9.6发过催稿信官方回复）

5 0

[GetPortalCommentsPageByObjectIdResponse(id=2225394, encodeId=10cb222539483, content=9.01 submit 9.02 with editor 9.12 还是 with editor，这啥情况啊能不能痛快点, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=025b6459612, createdName=ms5000001558887674, createdTime=Thu Sep 12 14:34:51 CST 2024, time=2024-09-12, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2225009, encodeId=a17b22250095a, content=审稿速度:3.0 偏重的研究方向：肿瘤 经验分享：2024-7-31 submit 2024-8-9 under review 2024-8-22 under review 2024-9-5 一个审稿人完成审稿 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e3ef6418566, createdName=ms3000000081429133, createdTime=Tue Sep 10 15:35:43 CST 2024, time=2024-09-10, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1231418, encodeId=a1c912314180d, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：泌尿系统肿瘤 经验分享：投稿一个多月就decision, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=cd131929695, createdName=石冰水寒, createdTime=Fri Jul 08 23:50:37 CST 2022, time=2022-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2223093, encodeId=1b89222309325, content=20240826从cancer letters转投过来的，20240827变成with editor, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57c56585599, createdName=ms1000000366960686, createdTime=Thu Aug 29 21:47:22 CST 2024, time=2024-08-29, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2224802, encodeId=91ba2224802bb, content=6.4投稿之后we 6.9 ur 8.23 小修当天修回 9.9 仍然是Revision Submitted to Journal （9.6发过催稿信官方回复）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b5c8431154, createdName=ms2000002142798745, createdTime=Mon Sep 09 12:24:12 CST 2024, time=2024-09-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2224164, encodeId=32d5222416446, content=已经投了半个月了还是with editor,真的拒的话能不能给个痛快啊这也太慢了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=21a65422215, createdName=小L爱科研, createdTime=Thu Sep 05 10:48:15 CST 2024, time=2024-09-05, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2217940, encodeId=137f221e940f6, content=偏重的研究方向：肿瘤 经验分享：7.16 submit 7.17 with editor 7.25 with editor 状态没变时间变 7.31 dip 是不是拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79a19302650, createdName=派大星的海绵**, createdTime=Thu Aug 01 10:44:13 CST 2024, time=2024-08-01, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2218424, encodeId=2c2b221842440, content=偏重的研究方向：肿瘤 经验分享：7.21投稿，7.23 with editor, 7.31 Decision in Process,这是不是要被拒了呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/4AEFTDxtTLcicl4SBQst8KS16TvccEdKUdYlCe0Rsu73iaW3GgcO1wZmD6PDPwf4a9kadNYiaTic1iadbgAicWWgFzBQ/132, createdBy=026e2391043, createdName=lialunxi, createdTime=Sun Aug 04 17:12:42 CST 2024, time=2024-08-04, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2221228, encodeId=995a2221228c3, content=偏重的研究方向：肿瘤 经验分享：7.31 提交然后 with editor，8.18 decision in process 是不是要被拒了…, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1668229032, createdName=ms7000001281118581, createdTime=Mon Aug 19 01:26:38 CST 2024, time=2024-08-19, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2218959, encodeId=aa8f221895946, content=7.30投了1篇；7.31 with editor； 8.6 under review，公众号查询一个审稿员接受邀请；看大家这个状态会很长时间，揪心。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9f99339818, createdName=ms7000000778834027, createdTime=Wed Aug 07 17:05:11 CST 2024, time=2024-08-07, status=1, ipAttribution=湖北省)]

2024-09-05 小L爱科研来自上海

已经投了半个月了还是with editor,真的拒的话能不能给个痛快啊这也太慢了

6 0

[GetPortalCommentsPageByObjectIdResponse(id=2225394, encodeId=10cb222539483, content=9.01 submit 9.02 with editor 9.12 还是 with editor，这啥情况啊能不能痛快点, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=025b6459612, createdName=ms5000001558887674, createdTime=Thu Sep 12 14:34:51 CST 2024, time=2024-09-12, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2225009, encodeId=a17b22250095a, content=审稿速度:3.0 偏重的研究方向：肿瘤 经验分享：2024-7-31 submit 2024-8-9 under review 2024-8-22 under review 2024-9-5 一个审稿人完成审稿 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e3ef6418566, createdName=ms3000000081429133, createdTime=Tue Sep 10 15:35:43 CST 2024, time=2024-09-10, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1231418, encodeId=a1c912314180d, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：泌尿系统肿瘤 经验分享：投稿一个多月就decision, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=cd131929695, createdName=石冰水寒, createdTime=Fri Jul 08 23:50:37 CST 2022, time=2022-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2223093, encodeId=1b89222309325, content=20240826从cancer letters转投过来的，20240827变成with editor, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57c56585599, createdName=ms1000000366960686, createdTime=Thu Aug 29 21:47:22 CST 2024, time=2024-08-29, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2224802, encodeId=91ba2224802bb, content=6.4投稿之后we 6.9 ur 8.23 小修当天修回 9.9 仍然是Revision Submitted to Journal （9.6发过催稿信官方回复）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b5c8431154, createdName=ms2000002142798745, createdTime=Mon Sep 09 12:24:12 CST 2024, time=2024-09-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2224164, encodeId=32d5222416446, content=已经投了半个月了还是with editor,真的拒的话能不能给个痛快啊这也太慢了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=21a65422215, createdName=小L爱科研, createdTime=Thu Sep 05 10:48:15 CST 2024, time=2024-09-05, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2217940, encodeId=137f221e940f6, content=偏重的研究方向：肿瘤 经验分享：7.16 submit 7.17 with editor 7.25 with editor 状态没变时间变 7.31 dip 是不是拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79a19302650, createdName=派大星的海绵**, createdTime=Thu Aug 01 10:44:13 CST 2024, time=2024-08-01, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2218424, encodeId=2c2b221842440, content=偏重的研究方向：肿瘤 经验分享：7.21投稿，7.23 with editor, 7.31 Decision in Process,这是不是要被拒了呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/4AEFTDxtTLcicl4SBQst8KS16TvccEdKUdYlCe0Rsu73iaW3GgcO1wZmD6PDPwf4a9kadNYiaTic1iadbgAicWWgFzBQ/132, createdBy=026e2391043, createdName=lialunxi, createdTime=Sun Aug 04 17:12:42 CST 2024, time=2024-08-04, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2221228, encodeId=995a2221228c3, content=偏重的研究方向：肿瘤 经验分享：7.31 提交然后 with editor，8.18 decision in process 是不是要被拒了…, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1668229032, createdName=ms7000001281118581, createdTime=Mon Aug 19 01:26:38 CST 2024, time=2024-08-19, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2218959, encodeId=aa8f221895946, content=7.30投了1篇；7.31 with editor； 8.6 under review，公众号查询一个审稿员接受邀请；看大家这个状态会很长时间，揪心。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9f99339818, createdName=ms7000000778834027, createdTime=Wed Aug 07 17:05:11 CST 2024, time=2024-08-07, status=1, ipAttribution=湖北省)]

2024-08-01 派大星的海绵** 来自天津

偏重的研究方向：肿瘤
经验分享：7.16 submit 7.17 with editor 7.25 with editor 状态没变时间变 7.31 dip 是不是拒了

47 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=2225394, encodeId=10cb222539483, content=9.01 submit 9.02 with editor 9.12 还是 with editor，这啥情况啊能不能痛快点, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=025b6459612, createdName=ms5000001558887674, createdTime=Thu Sep 12 14:34:51 CST 2024, time=2024-09-12, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2225009, encodeId=a17b22250095a, content=审稿速度:3.0 偏重的研究方向：肿瘤 经验分享：2024-7-31 submit 2024-8-9 under review 2024-8-22 under review 2024-9-5 一个审稿人完成审稿 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e3ef6418566, createdName=ms3000000081429133, createdTime=Tue Sep 10 15:35:43 CST 2024, time=2024-09-10, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1231418, encodeId=a1c912314180d, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：泌尿系统肿瘤 经验分享：投稿一个多月就decision, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=cd131929695, createdName=石冰水寒, createdTime=Fri Jul 08 23:50:37 CST 2022, time=2022-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2223093, encodeId=1b89222309325, content=20240826从cancer letters转投过来的，20240827变成with editor, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57c56585599, createdName=ms1000000366960686, createdTime=Thu Aug 29 21:47:22 CST 2024, time=2024-08-29, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2224802, encodeId=91ba2224802bb, content=6.4投稿之后we 6.9 ur 8.23 小修当天修回 9.9 仍然是Revision Submitted to Journal （9.6发过催稿信官方回复）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b5c8431154, createdName=ms2000002142798745, createdTime=Mon Sep 09 12:24:12 CST 2024, time=2024-09-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2224164, encodeId=32d5222416446, content=已经投了半个月了还是with editor,真的拒的话能不能给个痛快啊这也太慢了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=21a65422215, createdName=小L爱科研, createdTime=Thu Sep 05 10:48:15 CST 2024, time=2024-09-05, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2217940, encodeId=137f221e940f6, content=偏重的研究方向：肿瘤 经验分享：7.16 submit 7.17 with editor 7.25 with editor 状态没变时间变 7.31 dip 是不是拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79a19302650, createdName=派大星的海绵**, createdTime=Thu Aug 01 10:44:13 CST 2024, time=2024-08-01, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2218424, encodeId=2c2b221842440, content=偏重的研究方向：肿瘤 经验分享：7.21投稿，7.23 with editor, 7.31 Decision in Process,这是不是要被拒了呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/4AEFTDxtTLcicl4SBQst8KS16TvccEdKUdYlCe0Rsu73iaW3GgcO1wZmD6PDPwf4a9kadNYiaTic1iadbgAicWWgFzBQ/132, createdBy=026e2391043, createdName=lialunxi, createdTime=Sun Aug 04 17:12:42 CST 2024, time=2024-08-04, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2221228, encodeId=995a2221228c3, content=偏重的研究方向：肿瘤 经验分享：7.31 提交然后 with editor，8.18 decision in process 是不是要被拒了…, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1668229032, createdName=ms7000001281118581, createdTime=Mon Aug 19 01:26:38 CST 2024, time=2024-08-19, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2218959, encodeId=aa8f221895946, content=7.30投了1篇；7.31 with editor； 8.6 under review，公众号查询一个审稿员接受邀请；看大家这个状态会很长时间，揪心。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9f99339818, createdName=ms7000000778834027, createdTime=Wed Aug 07 17:05:11 CST 2024, time=2024-08-07, status=1, ipAttribution=湖北省)]

2024-08-04 lialunxi 来自湖南省

偏重的研究方向：肿瘤
经验分享：7.21投稿，7.23 with editor, 7.31 Decision in Process,这是不是要被拒了呀？

46 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=2225394, encodeId=10cb222539483, content=9.01 submit 9.02 with editor 9.12 还是 with editor，这啥情况啊能不能痛快点, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=025b6459612, createdName=ms5000001558887674, createdTime=Thu Sep 12 14:34:51 CST 2024, time=2024-09-12, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2225009, encodeId=a17b22250095a, content=审稿速度:3.0 偏重的研究方向：肿瘤 经验分享：2024-7-31 submit 2024-8-9 under review 2024-8-22 under review 2024-9-5 一个审稿人完成审稿 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e3ef6418566, createdName=ms3000000081429133, createdTime=Tue Sep 10 15:35:43 CST 2024, time=2024-09-10, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1231418, encodeId=a1c912314180d, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：泌尿系统肿瘤 经验分享：投稿一个多月就decision, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=cd131929695, createdName=石冰水寒, createdTime=Fri Jul 08 23:50:37 CST 2022, time=2022-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2223093, encodeId=1b89222309325, content=20240826从cancer letters转投过来的，20240827变成with editor, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57c56585599, createdName=ms1000000366960686, createdTime=Thu Aug 29 21:47:22 CST 2024, time=2024-08-29, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2224802, encodeId=91ba2224802bb, content=6.4投稿之后we 6.9 ur 8.23 小修当天修回 9.9 仍然是Revision Submitted to Journal （9.6发过催稿信官方回复）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b5c8431154, createdName=ms2000002142798745, createdTime=Mon Sep 09 12:24:12 CST 2024, time=2024-09-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2224164, encodeId=32d5222416446, content=已经投了半个月了还是with editor,真的拒的话能不能给个痛快啊这也太慢了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=21a65422215, createdName=小L爱科研, createdTime=Thu Sep 05 10:48:15 CST 2024, time=2024-09-05, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2217940, encodeId=137f221e940f6, content=偏重的研究方向：肿瘤 经验分享：7.16 submit 7.17 with editor 7.25 with editor 状态没变时间变 7.31 dip 是不是拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79a19302650, createdName=派大星的海绵**, createdTime=Thu Aug 01 10:44:13 CST 2024, time=2024-08-01, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2218424, encodeId=2c2b221842440, content=偏重的研究方向：肿瘤 经验分享：7.21投稿，7.23 with editor, 7.31 Decision in Process,这是不是要被拒了呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/4AEFTDxtTLcicl4SBQst8KS16TvccEdKUdYlCe0Rsu73iaW3GgcO1wZmD6PDPwf4a9kadNYiaTic1iadbgAicWWgFzBQ/132, createdBy=026e2391043, createdName=lialunxi, createdTime=Sun Aug 04 17:12:42 CST 2024, time=2024-08-04, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2221228, encodeId=995a2221228c3, content=偏重的研究方向：肿瘤 经验分享：7.31 提交然后 with editor，8.18 decision in process 是不是要被拒了…, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1668229032, createdName=ms7000001281118581, createdTime=Mon Aug 19 01:26:38 CST 2024, time=2024-08-19, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2218959, encodeId=aa8f221895946, content=7.30投了1篇；7.31 with editor； 8.6 under review，公众号查询一个审稿员接受邀请；看大家这个状态会很长时间，揪心。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9f99339818, createdName=ms7000000778834027, createdTime=Wed Aug 07 17:05:11 CST 2024, time=2024-08-07, status=1, ipAttribution=湖北省)]

2024-08-19 ms7000001281118581 来自海南省

偏重的研究方向：肿瘤
经验分享：7.31 提交然后 with editor，8.18 decision in process 是不是要被拒了…

41 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2225394, encodeId=10cb222539483, content=9.01 submit 9.02 with editor 9.12 还是 with editor，这啥情况啊能不能痛快点, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=025b6459612, createdName=ms5000001558887674, createdTime=Thu Sep 12 14:34:51 CST 2024, time=2024-09-12, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2225009, encodeId=a17b22250095a, content=审稿速度:3.0 偏重的研究方向：肿瘤 经验分享：2024-7-31 submit 2024-8-9 under review 2024-8-22 under review 2024-9-5 一个审稿人完成审稿 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e3ef6418566, createdName=ms3000000081429133, createdTime=Tue Sep 10 15:35:43 CST 2024, time=2024-09-10, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1231418, encodeId=a1c912314180d, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：泌尿系统肿瘤 经验分享：投稿一个多月就decision, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=120, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=cd131929695, createdName=石冰水寒, createdTime=Fri Jul 08 23:50:37 CST 2022, time=2022-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2223093, encodeId=1b89222309325, content=20240826从cancer letters转投过来的，20240827变成with editor, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57c56585599, createdName=ms1000000366960686, createdTime=Thu Aug 29 21:47:22 CST 2024, time=2024-08-29, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2224802, encodeId=91ba2224802bb, content=6.4投稿之后we 6.9 ur 8.23 小修当天修回 9.9 仍然是Revision Submitted to Journal （9.6发过催稿信官方回复）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b5c8431154, createdName=ms2000002142798745, createdTime=Mon Sep 09 12:24:12 CST 2024, time=2024-09-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2224164, encodeId=32d5222416446, content=已经投了半个月了还是with editor,真的拒的话能不能给个痛快啊这也太慢了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=21a65422215, createdName=小L爱科研, createdTime=Thu Sep 05 10:48:15 CST 2024, time=2024-09-05, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2217940, encodeId=137f221e940f6, content=偏重的研究方向：肿瘤 经验分享：7.16 submit 7.17 with editor 7.25 with editor 状态没变时间变 7.31 dip 是不是拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79a19302650, createdName=派大星的海绵**, createdTime=Thu Aug 01 10:44:13 CST 2024, time=2024-08-01, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2218424, encodeId=2c2b221842440, content=偏重的研究方向：肿瘤 经验分享：7.21投稿，7.23 with editor, 7.31 Decision in Process,这是不是要被拒了呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/4AEFTDxtTLcicl4SBQst8KS16TvccEdKUdYlCe0Rsu73iaW3GgcO1wZmD6PDPwf4a9kadNYiaTic1iadbgAicWWgFzBQ/132, createdBy=026e2391043, createdName=lialunxi, createdTime=Sun Aug 04 17:12:42 CST 2024, time=2024-08-04, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2221228, encodeId=995a2221228c3, content=偏重的研究方向：肿瘤 经验分享：7.31 提交然后 with editor，8.18 decision in process 是不是要被拒了…, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1668229032, createdName=ms7000001281118581, createdTime=Mon Aug 19 01:26:38 CST 2024, time=2024-08-19, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2218959, encodeId=aa8f221895946, content=7.30投了1篇；7.31 with editor； 8.6 under review，公众号查询一个审稿员接受邀请；看大家这个状态会很长时间，揪心。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9f99339818, createdName=ms7000000778834027, createdTime=Wed Aug 07 17:05:11 CST 2024, time=2024-08-07, status=1, ipAttribution=湖北省)]

2024-08-07 ms7000000778834027 来自湖北省

7.30投了1篇；7.31 with editor； 8.6 under review，公众号查询一个审稿员接受邀请；看大家这个状态会很长时间，揪心。

42 3

展开3条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务